Navigation Links
Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies

PROVO, Utah, Nov. 14, 2012 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) announced today that it has signed an agreement to acquire NOX Technologies, Inc., a biotechnology and biodiagnostic company based in Malvern, Pennsylvania for $12.5 million. The agreement includes the acquisition of technology and patents, including previously licensed technology already utilized in connection with Nu Skin's anti-aging research efforts.

"The acquisition of NOX Technologies demonstrates our ongoing commitment to scientific innovation and provides us with additional tools to target the sources of aging," said Chief Scientific Officer Joe Chang, Ph.D. "Furthermore, we believe the acquisition will enhance our long-term pipeline of scientifically validated anti-aging solutions for health, beauty and wellness."

NOX Technologies provides Nu Skin scientists with a deeper understanding of the aging process and supports the company's ability to understand important sources of aging. arNOX, an age-related protein identified by NOX Technologies, is found on the cell surface and is capable of superoxide generation, a relevant aspect of the aging process.

According to Thomas B. Shelton, chief executive officer of NOX Technologies, "This merger is the culmination of many years of working with Nu Skin researchers on our arNOX technology. NOX Technologies' translation of the basic science around arNOX paved the way for this unique technology to be incorporated into Nu Skin's successful anti-aging research and development efforts."

The acquisition is subject to customary closing conditions, including approval of the transaction by the stockholders of NOX Technologies, Inc.  Closing is expected to occur prior to the end of 2012.

About NOX Technologies, Inc.
Established in 2003, NOX Technologies, Inc. is a biotechnology and biodiagnostic company focused on the identification, characterization and detection of cell surface proteins relating to aging. Through its research and development efforts, NOX Technologies identified agents that interact with age-related ECTO-NOX proteins (arNOX).

NOX Technologies' discovery of specific inhibitors of arNOX that potentially ameliorate skin damage and the signs of aging led to Nu Skin's development of specific skin care products that are useful for improving the youthful appearance of the skin.

About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. The company's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company. The company's anti-aging products feature the new ageLOC® suite of products including the ageLOC®R2 nutritional supplement, ageLOC® Galvanic Spa System and ageLOC Galvanic Body Spa™, as well as the ageLOC® Transformation daily skin care system. A global direct selling company, Nu Skin operates in 53 markets worldwide and has more than 900,000 active distributors and preferred customers. Nu Skin is traded on the New York Stock Exchange under the symbol 'NUS'. More information is available at

Please Note: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations and beliefs regarding the company's acquisition of NOX Technologies, Inc.; statements regarding acquisition timing, terms and conditions; statements regarding the impact of the acquisition on the company's scientific research and product development efforts; statements regarding the company's plans and strategies; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

  • risks that the acquisition may not be completed or may cost more or take longer to complete than anticipated; and
  • risks related to the company's ability to effectively integrate and utilize NOX Technologies, Inc. in the company's scientific research and product development efforts.

The forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission.  The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

SOURCE Nu Skin Enterprises, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
2. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
3. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
4. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
5. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
6. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
7. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
8. The Trendlines Group Announces Co-development Agreement with Endo
9. No on Prop. 37: French Rat Study Author Made Reporters Sign Confidentiality Agreements Prohibiting them from Consulting Independent Scientific Experts
10. LLSs Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
11. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, today announced ... meetings taking place in the month of October: ... Forum RepliCel will be presenting at the annual ... the Mesa to be held October 7-9 in ...
(Date:10/8/2015)... TORONTO, CANADA (PRWEB) , ... October 08, 2015 ... ... it has entered into an exclusive license agreement to develop and commercialize intellectual ... expands upon the original agreement from February 2009, and affords exclusive worldwide rights ...
(Date:10/7/2015)... ... 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal ... Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the ... He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute ...
(Date:10/7/2015)...   PDI , a leader in infection prevention ... key challenges across various healthcare settings, as well as ... This tool is part of a larger effort to ... efficiencies and lower healthcare-associated infections. ... of how to use the right product, in the ...
Breaking Biology Technology:
... Annual Samter Journalism Awards ... Entry Deadline: October 31, 2007, MILWAUKEE, ... (AAAAI), the largest professional medical specialty,organization in the United States ... a special interest in the research and treatment of allergic ...
... CALGARY, Sept. 28 /PRNewswire-FirstCall/ - Oncolytics Biotech ... oral,presentation covering interim results from a U.K. ... for patients with advanced or,metastatic cancers is ... Cancer,Research Institute (NCRI) conference on October 2, ...
... Sept. 28 Cynosure, Inc.,(Nasdaq: CYNO ), ... array of,light-based aesthetic treatment systems, today announced that ... Company/MEDACorp Aesthetics Roundtable,Conference. Chief Financial Officer Timothy ... recent financial results in a presentation,beginning at 2:10 ...
Cached Biology Technology:
(Date:10/8/2015)... , 8. Oktober 2015 Die ... tätiges Unternehmen des Bereiches Tracking, hat heute ... der Gefängnisbehörde Virginias (Department of Corrections – ... Überwachungsdienste für alle Strafen geliefert werden, die ... , Präsident für den Amerikanischen Kontinent der ...
(Date:10/7/2015)... October 8, 2015 --> ... Fingerprint Cards (FPC) during third quarter 2015 amounted to around ... around 860 MSEK that was communicated 20 August 2015. ... strengthened delivery capacity and a continued growing demand for the ... estimated to be higher than during the third quarter. The ...
(Date:10/6/2015)... Oct. 6, 2015 Track Group, Inc. (OTCQX: ... it has signed a contract with the Virginia Department ... full range of sentences under the Department,s oversight. ... Americas. "This contract with the Virginia DOC will expand ... and advances our position as a trusted leader in ...
Breaking Biology News(10 mins):
... Columbia have been able to pinpoint more of the ... valuable compounds to the roasting process. Lead author ... the prevailing antioxidants present in dark roasted coffee brew ... high temperatures. Their findings will appear in ...
... Zaragoza (UNIZAR) has studied precipitation trends in Spain,s 10 ... results show that precipitation has declined overall between the ... the rainy season. The rains are heavier in October ... 1946, the average precipitation falling on Spanish hydrological basins ...
... a serious environmental, economic and social problem worldwide as ... ecosystem functions, such as nutrient cycling. Despite substantial research, ... new habitats over native plants that technically should have ... is that these plants are more abundant in introduced ...
Cached Biology News:
Human IL-19 MAb (Clone 152112)...
geminin, DNA replication inhibitor...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Human IL-17D Affinity Purified Polyclonal Ab...
Biology Products: